Colorectal Cancer Crc Pipeline Insight

DelveInsight’s, “Colorectal Cancer - Pipeline Insight, 2023,” report provides comprehensive insights about 145+ companies and 150+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Colorectal Cancer Understanding

Colorectal Cancer: Overview

Colorectal cancer (CRC) is a disorder that occurs exclusively in the colon or rectum and is caused by the colon’s aberrant proliferation of glandular epithelial cells. There are three principal types of CRC: sporadic, hereditary, and colitis-associated. The number of CRC cases is increasing globally day by day. Both environmental and genetic factors determine the risk of developing CRC. In addition, the risk of developing CRC in patients with long-standing ulcerative colitis and Crohn’s disease increases with age. Multiple studies have demonstrated that risk factors for CRC include diet and lifestyle, family history, and chronic inflammation.

CRC is a multifactorial disease. The epithelial cells of colorectal mucosa can undergo hyperplasia, atypical hyperplasia (mild, moderate, or severe), and adenomas that can eventually develop into carcinoma. This process is usually initiated by carcinogenic factors, causing structural changes in DNA and leading to the malignant transformation of cells into cancer. Morphology includes epithelial hyperplasia, atypical hyperplasia, adenoma formation, carcinoma in situ, and invasive carcinoma. In 1990, Fearon and Vogelstein proposed a molecular event model for the occurrence and development of CRC. With the development of research, three molecular mechanisms related to the occurrence and development of CRC have been confirmed: (i) chromosomal instability that mainly occurs in FAP; (ii) genetic mutations such as in Lynch syndrome and other sporadic MMR mutations; and (iii) hypermethylation of CPG islands in specific gene promoter regions. These processes are often associated with abnormal changes in multiple genes such as APC, DCC, P53, K-ras, c-MYC, MCC, and MMR-related genes (hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2). It is worth noting that these abnormal molecular signaling pathways are not mutually exclusive, and multiple abnormal molecular pathways are co-existing in some CRC patients.

Colorectal cancer (cancer of the colon or rectum) is very treatable when it is discovered early. Even if it spreads into nearby lymph nodes, surgical treatment followed by chemotherapy is very effective. In the most advanced cases — when the cancer has spread to the liver, lungs, or other sites — treatment can often make surgery an option, and can prolong and add to quality of life. The application of molecularly targeted drugs has brought significant benefits to CRC patients. Currently, molecularly targeted drugs are used in the clinical treatment of CRC. Clinically, molecular-targeted drugs are recommended to be used in combination with chemotherapeutic drugs because they are non-cytotoxic drugs and have relatively mild adverse reactions, which generally do not significantly increase the adverse reactions of chemotherapy. Recent studies have shown that immunotherapy can prolong survival in CRC patients.

"Colorectal Cancer - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Colorectal Cancer pipeline landscape is provided which includes the disease overview and Colorectal Cancer treatment guidelines. The assessment part of the report embraces, in depth Colorectal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Colorectal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.

Colorectal Cancer Emerging Drugs Chapters

This segment of the Colorectal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Colorectal Cancer Emerging Drugs

Adagrasib: Mirati Therapeutics

Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Mirati has an Expanded Access Program (EAP) for investigational adagrasib for the treatment of eligible patients with KRASG12C-mutated cancers, regardless of tumor type, including patients with treated or untreated CNS metastases, in the US. Adagrasib demonstrated promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. Currently, it is being investigated in the Phase III stage of development for the treatment of Colorectal Cancer.

XL092: Exelixis

XL092 targets VEGF receptors, MET, TAM kinases, and other kinases implicated in cancer’s growth and spread. In preclinical tumor models, XL092 showed excellent activity as a single agent and in combination with ICIs. XL092 also has an optimized pharmacokinetic profile aimed at facilitating adverse event management in the clinic. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Colorectal Cancer.

EO2040: Enterome

EO2040 is an innovative, off-the-shelf, peptide-based immunotherapy that includes two OncoMimics peptides (bacterial peptides). EO2040 is being evaluated in a Phase II clinical trial as monotherapy and in combination with a checkpoint inhibitor (nivolumab) in patients with circulating tumor DNA-defined minimal residual disease (MRD) relapse of advanced colorectal cancer.

Etrumadenant: Arcus Biosciences

Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS-mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Colorectal Cancer.

LYL845: Lyell Immunopharma

LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology. TIL products are created by expanding T cells taken from the patient’s own tumor. Previous clinical experiences suggest that the efficacy of adoptive transfer of ex vivo expanded TILs is largely driven by specific recognition of mutated tumor neo antigens specific to each patient. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of colorectal cancer.

Further product details are provided in the report……..

Colorectal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Colorectal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Colorectal Cancer

There are approx. 145+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Colorectal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Colorectal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Colorectal Cancer drugs.

Colorectal Cancer Report Insights

• Colorectal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Colorectal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Colorectal Cancer drugs?
• How many Colorectal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Colorectal Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Colorectal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Colorectal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?